BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 18414107)

  • 41. Using diurnal intraocular pressure fluctuation to assess the efficacy of fixed-combination latanoprost/timolol versus latanoprost or timolol monotherapy.
    Varma R; Hwang LJ; Grunden JW; Bean GW
    Br J Ophthalmol; 2010 Jan; 94(1):80-4. PubMed ID: 19692375
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A comparison of the safety and intraocular pressure lowering of bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in patients with open-angle glaucoma.
    Martinez A; Sanchez M
    Curr Med Res Opin; 2007 May; 23(5):1025-32. PubMed ID: 17519068
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MERCURY-3: a randomized comparison of netarsudil/latanoprost and bimatoprost/timolol in open-angle glaucoma and ocular hypertension.
    Stalmans I; Lim KS; Oddone F; Fichtl M; Belda JI; Hommer A; Laganovska G; Schweitzer C; Voykov B; Zarnowski T; Holló G
    Graefes Arch Clin Exp Ophthalmol; 2024 Jan; 262(1):179-190. PubMed ID: 37615697
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The safety and efficacy of bimatoprost/timolol fixed combination: a 1-year double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension.
    Lewis RA; Gross RL; Sall KN; Schiffman RM; Liu CC; Batoosingh AL;
    J Glaucoma; 2010 Aug; 19(6):424-6. PubMed ID: 19855289
    [No Abstract]   [Full Text] [Related]  

  • 45. Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%.
    Kaback M; Scoper SV; Arzeno G; James JE; Hua SY; Salem C; Dickerson JE; Landry TA; Bergamini MV;
    Ophthalmology; 2008 Oct; 115(10):1728-34, 1734.e1-2. PubMed ID: 18538406
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Observational study of patients switched to the fixed travoprost 0.004%/timolol 0.5% combination in Croatia.
    Mandic Z; Novak-Lauš K; Bojic L; Popovic-Suic S; Maricic-Došen V; Pelcic G; Dobutovic D; Biuk D; Kovacic Z; Pavan J
    Methods Find Exp Clin Pharmacol; 2010 Oct; 32(8):593-8. PubMed ID: 21132129
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.
    Sherwood MB; Craven ER; Chou C; DuBiner HB; Batoosingh AL; Schiffman RM; Whitcup SM
    Arch Ophthalmol; 2006 Sep; 124(9):1230-8. PubMed ID: 16966616
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Comparison of intraocular pressure lowering efficacy of bimatoprost / timolol fixed combination and other glaucoma medications in the treatment of glaucoma].
    Skorkovská K
    Cesk Slov Oftalmol; 2008 Jul; 64(4):144-8. PubMed ID: 18780653
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 24-Hour intraocular pressure control between travoprost/timolol fixed combination, latanoprost/ timolol fixed combination and standard timolol in primary open angle glaucoma and ocular hypertension.
    Pachimkul P; Yuttitham K; Thoophom P
    J Med Assoc Thai; 2011 Mar; 94 Suppl 2():S81-7. PubMed ID: 21717884
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension.
    Goldberg I; Cunha-Vaz J; Jakobsen JE; Nordmann JP; Trost E; Sullivan EK;
    J Glaucoma; 2001 Oct; 10(5):414-22. PubMed ID: 11711841
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy, safety, and tolerability of preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% versus concomitant use of the ingredients.
    Holló G; Hommer A; Antón López A; Ropo A
    J Ocul Pharmacol Ther; 2014 Aug; 30(6):468-75. PubMed ID: 24738883
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure.
    Sherwood M; Brandt J;
    Surv Ophthalmol; 2001 May; 45 Suppl 4():S361-8. PubMed ID: 11434939
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A randomised, double masked, multicentre clinical trial comparing bimatoprost and timolol for the treatment of glaucoma and ocular hypertension.
    Whitcup SM; Cantor LB; VanDenburgh AM; Chen K
    Br J Ophthalmol; 2003 Jan; 87(1):57-62. PubMed ID: 12488264
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Switching from concomitant latanoprost 0.005% and timolol 0.5% to a fixed combination of travoprost 0.004%/timolol 0.5% in patients with primary open-angle glaucoma and ocular hypertension: a 6-month, multicenter, cohort study.
    Rossi GC; Pasinetti GM; Bracchino M; Bucarelli M; Franchin S; Cerqueti P; Bellini R; Caravati C; Celesia L; Clemente A; Tinelli C
    Expert Opin Pharmacother; 2009 Aug; 10(11):1705-11. PubMed ID: 19601697
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Brimonidine Purite and bimatoprost compared with timolol and latanoprost in patients with glaucoma and ocular hypertension.
    Netland PA; Michael M; Rosner SA; Katzman B; Macy JI
    Adv Ther; 2003; 20(1):20-30. PubMed ID: 12772815
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma.
    Holló G; Chiselita D; Petkova N; Cvenkel B; Liehneova I; Izgi B; Berta A; Szaflik J; Turacli E; Stewart WC
    Eur J Ophthalmol; 2006; 16(6):816-23. PubMed ID: 17191187
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Late-day intraocular pressure-lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial.
    DuBiner HB; Hubatsch DA
    BMC Ophthalmol; 2014 Nov; 14():151. PubMed ID: 25432143
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial.
    Fellman RL; Sullivan EK; Ratliff M; Silver LH; Whitson JT; Turner FD; Weiner AL; Davis AA;
    Ophthalmology; 2002 May; 109(5):998-1008. PubMed ID: 11986110
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial.
    Goldberg I; Gil Pina R; Lanzagorta-Aresti A; Schiffman RM; Liu C; Bejanian M
    Br J Ophthalmol; 2014 Jul; 98(7):926-31. PubMed ID: 24667994
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy.
    Kitazawa Y; Smith P; Sasaki N; Kotake S; Bae K; Iwamoto Y
    Eye (Lond); 2011 Sep; 25(9):1161-9. PubMed ID: 21701528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.